



Condensed Consolidated Interim Financial Statements
(Expressed in Canadian Dollars)

WAVERLEY PHARMA INC.

Three and nine months ended September 30, 2021
(unaudited)

In accordance with National Instruments 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited condensed consolidated interim financial statements for the three months ended September 30, 2021.



Condensed Consolidated Interim Statements of Financial Position
 (expressed in Canadian dollars)
 (unaudited)

	Note	September 30, 2021	December 31, 2020
Assets			
Current assets:			
Cash		\$ 138,276	\$ 710,492
Accounts receivable	3	692,439	455,936
Inventory	4	214,747	265,682
Prepaid expenses and other current assets		271,110	249,706
Total current assets		1,316,572	1,681,816
Non-current assets			
Intangible assets	5	1,794,115	1,810,072
Total non-current assets		1,794,115	1,810,072
Total assets		\$ 3,110,687	\$ 3,491,888
Liabilities and Equity			
Current liabilities:			
Accounts payable and accrued liabilities	8(b)	\$ 979,140	\$ 836,110
Current portion of license fee payable	8(b)	573,345	572,940
Total current liabilities		1,552,485	1,409,050
Non-current liabilities:			
Long-term loan payable	7	40,000	40,000
Total non-current liabilities		40,000	40,000
Total liabilities		1,592,485	1,449,050
Equity:			
Share capital	6(b)	7,000,100	7,000,100
Contributed surplus		808,709	809,159
Accumulated other comprehensive income		(51,621)	(55,908)
Deficit		(6,238,986)	(5,710,513)
Total equity		1,518,202	2,042,838
Total liabilities and equity		\$ 3,110,687	\$ 3,491,888

Commitments and contingencies (Note 8)

See accompanying notes to the condensed consolidated interim financial statements.



Condensed Consolidated Interim Statements of Net (Loss) Income and Comprehensive Loss
(expressed in Canadian dollars)
(unaudited)

	Note	Three months ended September 30, 2021	Three months ended September 30, 2020	Nine months ended September 30, 2021	Nine months ended September 30, 2020
Revenue from contracts with customers		\$ 382,721	\$ 353,305	\$ 1,286,073	\$ 949,521
Cost of goods sold	4	326,293	252,003	1,076,189	865,021
Gross Profit		56,428	101,302	209,884	84,500
Expenses:					
Selling, general and administrative		245,663	211,848	682,368	547,503
Research and development		11,727	3,896	26,423	43,904
		257,390	215,744	708,791	591,407
Loss before the undernoted		(200,962)	(114,442)	(498,907)	(506,907)
Other income:					
Loss recovery under profit sharing arrangement	8(b)	-	(123,705)	-	(123,705)
			-	-	(123,705)
Finance expense (income):					
Finance expense (income), net		471	3,237	282	(2,922)
Foreign exchange loss (gain), net		5,815	5,037	29,284	3,329
		6,286	8,274	29,566	407
Net (loss) income		\$ (207,248)	\$ 989	\$ (528,473)	\$ (383,609)
Translation adjustment		36,488	(44,108)	4,287	(34,246)
Comprehensive loss		\$ (170,760)	\$ (43,119)	\$ (524,186)	\$ (417,855)
(Loss) income per share attributable to shareholders:					
Basic and Diluted	6(e)	\$ -	\$ -	\$ (0.01)	\$ (0.01)
Weighted average shares outstanding:					
Basic and Diluted	6(e)	54,000,000	54,000,000	54,000,000	54,000,000

See accompanying notes to the condensed consolidated interim financial statements.



Condensed Consolidated Interim Statements of Changes in Equity
 (expressed in Canadian dollars)
 (unaudited)

	Note	Share Capital	Contributed surplus	Accumulated other comprehensive income (loss)	Deficit	Total
Balance, December 31, 2019		\$ 7,000,100	\$ 825,560	\$ 24,417	\$ (5,004,750)	\$ 2,845,327
Net loss for the nine months ended September 30, 2020		-	-	-	(383,609)	(383,609)
Other comprehensive loss for the nine months ended September 30, 2020		-	-	(34,246)	-	(34,246)
Stock-based compensation	6(c)	-	20,402	-	-	20,402
Balance, September 30, 2020		\$ 7,000,100	\$ 845,962	\$ (9,829)	\$ (5,388,359)	\$ 2,447,874
Balance, December 31, 2020		\$ 7,000,100	\$ 809,159	\$ (55,908)	\$ (5,710,513)	\$ 2,042,838
Net loss for the nine months ended September 30, 2021		-	-	-	(528,473)	(528,473)
Other comprehensive income for the nine months ended September 30, 2021		-	-	4,287	-	4,287
Stock-based compensation	6(c)	-	(450)	-	-	(450)
Balance, September 30, 2021		\$ 7,000,100	\$ 808,709	\$ (51,621)	\$ (6,238,986)	\$ 1,518,202

See accompanying notes to the condensed consolidated interim financial statements.



Condensed Consolidated Interim Statements of Cash Flows
 (expressed in Canadian dollars)
 (unaudited)

For the nine months ended September 30	Note	2021	2020
Cash (used in) provided by:			
Operating activities:			
Net loss for the period		\$ (528,473)	\$ (383,609)
Stock-based compensation	6(c)	(450)	20,402
Amortization of intangible assets	5	16,958	5,152
Changes in working capital accounts:			
Accounts receivable		(236,503)	527,191
Inventory		50,935	(172,415)
Prepaid expenses and other current assets		(21,404)	(263,409)
Accounts payable and accrued liabilities		143,030	(69,454)
Cash flows used in operating activities		(575,907)	(336,142)
Financing activities:			
Payments on license fees payable		-	(413,695)
Proceeds from long-term loan	7	-	40,000
Cash flows used in financing activities		-	(373,695)
Decrease in cash		\$ (575,907)	\$ (709,837)
Effect of exchange rate differences on cash		3,691	(44,503)
Cash, beginning of period		710,492	1,477,417
Cash, end of period		\$ 138,276	\$ 723,077

See accompanying notes to the condensed consolidated interim financial statements.



Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

1. Reporting entity:

Waverley Pharma Inc. ("**Waverley**" or the "**Company**") was incorporated as Buffalo Capital Inc. ("**Buffalo**") pursuant to the provisions of the Canada Business Corporations Act ("**CBCA**") on December 14, 2016 and was classified as a Capital Pool Corporation ("**CPC**") as defined by Policy 2.4 of the TSX Venture Exchange (the "**Exchange**"). On October 24, 2017, the Company completed a qualifying transaction (the "**QT**") with Waverley Pharma Inc. and resumed as Waverley Pharma Inc. in accordance with the CBCA.

The Company is domiciled and incorporated in Canada and its Common Shares are listed on Tier 2 of the Exchange under the symbol "WAVE". The address of the Company's registered office and head office is 4-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.

The Company is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. Through its wholly-owned Barbadian subsidiary, Waverley Pharma International Inc. ("**WPIL**"), the Company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited. ("**RLS**" or the "**Licensor**") by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (the "**UK**") and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Additionally, the Company has acquired exclusive territorial licenses from RLS to two oncologic drugs currently under development, pemetrexed (formerly known as WAV-101) and bortezomib (formerly known as WAV-102) in the United States and its territories (the "**USA**"), Canada, and the European Union (the "**EU**"). In addition, the Company has obtained a non-exclusive territorial license to sell both pemetrexed and bortezomib in the UK. These products are marketed through the Company's wholly-owned Irish subsidiary, Waverley Pharma Europe Limited ("**WPEL**").

2. Basis of preparation:

(a) Statement of compliance

These condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("**IFRS**") as issued by the International Accounting Standards Board ("**IASB**") and Interpretations issued by the International Financial Reporting Interpretations Committee ("**IFRIC**").

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard ("**IAS**") 34 *Interim Financial Reporting* and have been prepared using the same accounting policies and methods of application as those used in the Company's audited consolidated financial statements for the year ended December 31, 2020. These condensed consolidated interim financial statements do not include all of the information required for full annual consolidated financial statements and should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2020.

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors (the "**Board**") on November 24, 2021.

(b) Basis of presentation

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for financial instruments at fair value through profit or loss ("**FVTPL**") which are measured at fair value.

(c) Going concern

These condensed consolidated interim financial statements have been prepared on a going concern basis which contemplates the realization of assets and the payment of liabilities in the ordinary course of business. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and meet its liabilities as they become due.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

2. Basis of preparation (continued):

(c) Going concern (continued):

The Company is a research and development stage company and as such is primarily dependent on financing provided from external sources to continue as a going concern. Management intends to raise capital in order to fund its operations, however, the outcome of these matters cannot be predicted at this time. In addition, there is uncertainty surrounding the potential impacts of COVID-19 on the Company and its subsidiaries. The COVID-19 pandemic has resulted in uncertainties surrounding the shipment of products, fluctuations of foreign exchange, and delays in collections on accounts. Due to the preventive measures taken by the UK and EU with respect to preventing the spread of the virus, the Company is unable, at this time, to assess the future impact of COVID-19 on the Company and its subsidiaries' operations. In addition, during the nine-month period ended September 30, 2021, the Company incurred a net loss of \$528,473 (2020 - \$383,609), with cash used in operating activities of \$575,907 (2020 - \$336,142) and, as at September 30, 2021, has a deficit of \$6,238,986 (2020 - \$5,388,359).

The above noted events and conditions indicate that material uncertainties exist that may cast significant doubt upon the Company's ability to continue as a going concern. In the future, the Company's ability to continue as a going concern will be dependent upon its ability to attain profitable operations and generate funds there from, and to continue to obtain funds from equity financings or borrowings from third parties sufficient to meet current and future obligations and/or restructure the existing liabilities. These consolidated financial statements do not reflect the adjustments or reclassification of assets and liabilities which would be necessary if the Company were unable to continue its operations.

(d) Functional and presentation currency

The condensed consolidated interim financial statements are presented in Canadian dollars, which is the Company's functional currency. All financial information presented has been rounded to the nearest dollar except where indicated otherwise.

(e) Use of estimates and judgments

The preparation of condensed consolidated interim financial statements in conformity with IFRS requires management to make estimates, judgements and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses during the period.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Areas in which management has made critical judgments in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the condensed consolidated interim financial statements include the determination of the Company's and its subsidiaries' functional currencies.

Information about key assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are included in the following notes to the consolidated financial statements for the year ended December 31, 2020:

- Note 3(e): Estimates of variable consideration receivable from revenue from contracts with customers
- Note 3(g): Estimates of the measurement and valuation of inventory
- Note 3(h): Estimates of the measurement, valuation and period of use of intangible assets
- Note 3(l): Estimates and assessment of the recoverability of unused tax losses and deductible temporary differences
- Note 3(n): Estimates regarding assumptions used to estimate the value of share-based payment transactions and warrants



Notes to the Condensed Consolidated Interim Financial Statements
 (expressed in Canadian dollars)
 (unaudited)

3. Accounts receivable

	September 30, 2021	December 31, 2020
Trade accounts receivable	\$ 686,918	\$ 445,803
Other accounts receivable	5,521	10,133
	\$ 692,439	\$ 455,936

As at September 30, 2021, there was one customer with amounts owing greater than 10% of the Company's trade accounts receivable which totaled 100% in aggregate (December 31, 2020 – one customer totaling 100%).

4. Inventory

Inventory consists of finished product available for sale to customers. Inventory expensed as part of cost of goods sold during the three and nine months ended September 30, 2021 totaled \$326,293 and \$1,076,189, respectively (2020 – \$252,003 and \$865,021).

5. Intangible assets:

Cost	Licenses
Balance, December 31, 2019	\$ 1,854,509
License amortization	(8,172)
Effects of movements in exchange rates	(36,265)
Balance, December 31, 2020	\$ 1,810,072
License amortization	(16,958)
Effects of movements in exchange rates	1,001
Balance, September 30, 2021	\$ 1,794,115

On August 30, 2017, the Company acquired exclusive territorial licenses from RLS to sell and market two generic cancer drugs in the USA, Canada and the EU. In addition, the Company acquired a non-exclusive territorial license to market both products in the UK. As at September 30, 2021, bortezomib is still under development and was not commercialized. Therefore, the Company did not realize any amortization expense relating to the bortezomib license for the period ended September 30, 2021, or 2020.

As at September 30, 2021, the Company has completed its development of pemetrexed. The Company's first full month of commercialization for the product was in July 2021. As a result, the Company has commenced amortizing the pemetrexed license for the EU and the UK on a straight-line basis over ten years. The amortization expense is included in research and development expense on the condensed consolidated interim statements of net loss and comprehensive loss. The total amount of amortization recorded in relation to pemetrexed during the nine-month period ending September 30, 2021, was \$8,272 (2020 – nil).

On December 17, 2019, the Company acquired the rights to market erlotinib in the United Kingdom. The Company began selling the product during May 2020, and subsequently began amortizing the license on a straight-line basis over three years. The amortization expense is included in research and development expense on the condensed consolidated interim statements of net loss and comprehensive loss. The total amount of amortization recorded in relation to erlotinib during the nine-month period ending September 30, 2021, was \$8,686 (2020 – \$5,152).

The Company has considered indicators of impairment as at September 30, 2021 and 2020 and did not record an impairment charge in either the three months or nine months ended September 30, 2021 or 2020.



Notes to the Condensed Consolidated Interim Financial Statements
 (expressed in Canadian dollars)
 (unaudited)

6. Capital stock:

(a) Authorized

The Company has authorized share capital of an unlimited number of common voting shares.

(b) Shares issued and outstanding

Shares issued and outstanding are as follows:

	Number of Common Shares		Amount
Balance, December 31, 2019	54,000,000	\$	7,000,100
Balance, December 31, 2020	54,000,000	\$	7,000,100
Balance, September 30, 2021	54,000,000	\$	7,000,100

6. Capital stock (continued):

(c) Stock option plan

The Company has an incentive stock option plan (the “Plan”) whereby the Company may grant directors, officers, employees and contractors incentive stock options to purchase voting common shares of the Company. The terms and conditions of each option granted under the Plan are determined by the Board. The number of common shares reserved for issuance upon the exercise of options is limited to a maximum of 10% of the issued and outstanding common shares of the Company at any time.

The fair value of the stock options issued during the nine months ended September 30, 2020 was estimated using the following Black-Scholes Model assumptions:

Expected life	5 years
Expected volatility	55.00%
Risk free rate	1.29%
Dividend yield	-
Underlying share price	\$0.10
Strike price	\$0.10

Expected volatility was estimated by reference to comparable listed entities. Stock-based compensation expense (recovery) for the three and nine months ended September 30, 2021 amounted to \$(2,633) and \$(450), respectively, (2020 – \$11,684 and \$20,402) and was recorded in selling, general and administrative expenses during the period. The compensation expense (recovery) was determined based on the fair value of the options at the date of measurement using the Black-Scholes option pricing model. The expected life of stock options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

6. Capital stock (continued):

(c) Stock option plan (continued):

Changes in the number of options outstanding during the nine months ended September 30, 2021 and 2020 are as follows:

For the nine months ended September 30	2021		2020	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Balance, beginning of period	1,260,000	\$ 0.35	1,750,000	\$ 0.39
Granted	-	\$ -	275,000	\$ 0.10
Expired/Forfeited	(139,167)	\$ 0.42	(390,000)	\$ 0.26
Balance, end of period	1,120,833	\$ 0.34	1,635,000	\$ 0.37
Options exercisable, end of period	1,033,333	\$ 0.36	1,068,332	\$ 0.38

The following is a summary of the 1,120,833 outstanding options issued under the Plan:

Exercise price	Number outstanding	Weighted average remaining contractual life	Number exercisable	Weighted average remaining vesting period
\$0.100	262,500	3.3 years	175,000	0.1 years
\$0.200	225,000	5.6 years	225,000	-
\$0.285	33,333	3.2 years	33,333	-
\$0.500	600,000	6.1 years	600,000	-
	1,120,833		1,033,333	

(d) Warrants

Changes in the number of warrants outstanding during the nine months ended September 30, 2021 and 2020 are as follows:

Nine months ended September 30	2021		2020	
	Warrants	Weighted average exercise price	Warrants	Weighted average exercise price
Balance, beginning of period	-	\$ -	-	\$ -
Granted ⁽¹⁾	10,000,000	\$ 0.11	-	\$ -
Balance, end of period	10,000,000	\$ 0.11	-	\$ -

⁽¹⁾ On August 05, 2021, the Company entered into an agreement with its primary financial institution, pursuant to which the financial institution provided the Company with a credit facility with maximum aggregate proceeds of \$3,000,000. The collateral necessary to secure the credit facility was provided by a director of the Company. To compensate the director for providing the collateral for the credit facility, the Company granted the director 10,000,000 warrants. Each warrant entitles the holder to purchase one (1) common share of the Company and are exercisable within five years of the date of grant at an exercise price of \$0.11 per common share. Given the nature as to which the warrants were granted, the Company has elected to not record the warrants on its balance sheet unless the warrants are exercised.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

6. Capital stock (continued):

(d) Warrants (continued):

The fair value of the warrants issued during the nine months ended September 30, 2021 was estimated using the following Black-Scholes Model assumptions:

Expected life	5 years
Expected volatility	55.00%
Risk free rate	0.97%
Underlying share price	\$0.11
Strike price	\$0.11

(e) Per share amounts

The weighted average number of common voting shares outstanding for the three and nine months ended September 30, 2021 was 54,000,000 and 54,000,000, respectively (2020 – 54,000,000 and 54,000,000). Effects of dilution from 1,120,833 options and 10,000,000 warrants were excluded from the calculation of weighted average shares outstanding for diluted (loss) income per share for the three and nine months ended September 30, 2021 as they are anti-dilutive. Effects of dilution from 1,635,000 options were excluded from the calculation of weighted average shares outstanding for diluted loss per share for the three and nine months ended September 30, 2020 as they are anti-dilutive.

7. Government assistance

During the three and nine months ended September 30, 2021, the Company recorded \$nil and \$nil, respectively, (2020 – \$18,052 and \$45,130) in government assistance resulting from the Canada Emergency Wage Subsidy. The funding has been recorded as a reduction of the related salary expenditures within selling, general and administrative expenses.

During the three and nine months ended September 30, 2021, the Company recorded \$nil and \$2,665, respectively (2020 - \$18,000 and \$54,000) in government assistance resulting from a non-repayable grant received from the National Research Council of Canada Industrial Research Assistance Program (“**NRC IRAP**”). The grant was provided as financial assistance for salary expenditures in connection with the development of pemetrexed and bortezomib. The grant has been recorded as a reduction of salary expenditures within selling, general, and administrative expenses.

In addition, on June 29, 2020, the Company received \$40,000 as an interest-free loan from the government of Canada as part of the Canada Emergency Business Account (“**CEBA**”) program. The term loan is interest free until December 31, 2022, with an option for an extension until December 31, 2025, at an interest rate of 5% per annum. If the term loan is repaid prior to December 31, 2022, 25% of the loan will become forgivable. The amount has been recorded at its fair value which is approximately the amount noted within the CEBA loan agreement.

8. Commitments and contingencies:

(a) Commitments

As at September 30, 2021, and in the normal course of business, the Company has obligations to make future payments representing contracts and other commitments that are known and committed. The Company, through a subsidiary, WPEL has committed to purchase inventory totaling £211,639 (CAD \$362,389) and an office space lease at a rate of €908 (CAD \$1,335) per month for a term ending October 31, 2021. All commitments are current and expected to be settled within one year of September 30, 2021.

8. Commitments and contingencies (continued):

(b) Contingencies

June 7, 2018 agreement

On June 7, 2018, the Company through WPIL entered into a license, manufacture, supply, marketing and distribution agreement with RLS by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany and non-exclusive territorial license to market and sell temozolomide in the UK. Additionally, the Company has assumed the obligations associated with binding contracts held by the Licensor for the supply of these products to the UK National Health Service. All inventory purchased for resale will be purchased from RLS, in accordance with the June 7, 2018 agreement.

In addition, as part of the June 7, 2018 agreement, the Company was provided an option to obtain the market authorization rights to erlotinib in the UK. On December 17, 2019, the Company elected to exercise this option and obtained the rights to market erlotinib in the UK, and as of May 1, 2020, the Company began commercialization of erlotinib in the UK. Similar to both capecitabine and temozolomide, all inventory purchased for resale will be purchased from RLS, in accordance with the June 7, 2018 agreement.

In connection with the signing of the June 7, 2018 agreement, the Company entered into a profit and/or loss sharing arrangement resulting in a portion of the net profits, after a margin deduction to the Company on the sales of capecitabine, temozolomide and erlotinib to be paid to RLS. During the three and nine months ended September 30, 2021, the Company elected to not record a recovery from the profit and/or loss arrangement due to unforeseen delays in collections caused by COVID-19 (2020 – \$15,735 and \$15,735).

August 30, 2017 agreement

On August 30, 2017, the Company acquired exclusive licenses to sell and market two generic cancer drugs from RLS, in the USA, Canada and Europe (excluding the UK where a non-exclusive license was acquired). An up-front payment of US \$20,000 was made upon signing of the term sheet on July 5, 2017 and a US \$180,000 payment was made upon signing of the definitive documentation on August 30, 2017. Additional payments of US \$1,200,000 are payable upon certain development and approval-based milestones being met and as at September 30, 2021, the Company has paid US \$750,000 of the remaining US \$1,200,000 with US \$450,000 (CAD \$573,345) recorded as license fee payable. The amount recorded as license fee payable represents the remaining portion of the milestones which have not been met, the remaining milestone payments are recorded as current liabilities as they are expected to be met within one year of September 30, 2021. Additionally, the Company will purchase inventory and pay a royalty of 7.5% of its net sales from these two products to the Licensor. The term of the August 30, 2017 agreement is a period of ten (10) years, which begins when regulatory approval is obtained in the USA.

In connection with the August 30, 2017 agreement, the Company is obligated to pay a royalty of 7.5% of its net sales to the Licensor for the two generic products it acquired. The Company began commercialization of pemetrexed as of July 1, 2021, and has recorded a royalty payable to the Licensor for the three- and nine-month periods ending September 30, 2021 of \$6,358 and \$6,358, respectively (2020 - \$nil and \$nil). The royalty expense has been included as part of cost of goods sold on the condensed consolidated interim statements of net (loss) income and comprehensive loss.

Importation Value Added Tax Contingency

On October 7, 2020, the Company was made aware that the importation value added tax (“VAT”) its wholesaler had paid on its behalf from October 2018 to September 2019 had been rejected by Her Majesty’s Revenue and Customs (“HMRC”). The wholesaler had requested to claw back this amount from the Company, creating the possibility of a future liability. The Company is currently working with its consultants in the United Kingdom regarding the matter, however, as at September 30, 2021, there continues to be a provision of £65,165 (CAD \$111,582) recorded in relation to the potential liability.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

9. Related party transactions:

(a) Key management personnel compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, Chief Financial Officer and Chief Executive Officer of the Company are considered to be key management personnel.

The following table details the compensation paid to key management personnel:

	Three months ended September 30, 2021	Three months ended September 30, 2020	Nine months ended September 30, 2021	Nine months Ended September 30, 2020
Salaries, fees and short-term benefits	\$ 38,750	\$ 37,198	\$ 116,250	\$ 126,646
Stock-based compensation	527	8,622	1,931	34,673
	\$ 39,277	\$ 45,820	\$ 118,181	\$ 161,319

Directors and key management personnel control 75% of the voting shares of the Company as at September 30, 2021 (December 31, 2020 - 75%).

(b) Transactions with related parties

During the three and nine months ended September 30, 2021, the Company paid Genesys Venture Inc. ("GVI"), a company controlled by a director of the Company, a total of \$nil and \$nil respectively, (2020 – \$1,575 and \$4,725) for rental of office space and \$1,049 and \$3,620, respectively (2020 – \$1,138 and \$4,350) for business administration expenses.

These transactions were in the normal course of business and have been measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

As at September 30, 2021, included in accounts payable and accrued liabilities is \$421 (December 31, 2020 - \$2,112) payable to GVI, this amount is unsecured, payable on demand and non-interest bearing.

10. Segmented information:

The Company operates in one business segment, the biopharmaceutical industry. The Company's intangible assets are located in Barbados. All of the Company's revenue was generated from product sales within the UK, with one customer accounting for 100% of total revenue for the period ended September 30, 2021.